目 录 | 二、财务报表……………………………………………………… 第 8—15 | | | 页 | | --- | --- | --- | --- | | （一）合并资产负债表…………………………………………… | 第 | 8 页 | | | （二）母公司资产负债表………………………………………… | 第 | 9 页 | | | （三）合并利润表…………………………………………………第 | 10 | 页 | | | （四）母公司利润表………………………………………………第 | 11 | 页 | | | （五）合并现金流量表……………………………………………第 | 12 | 页 | | | （六）母公司现金流量表…………………………………………第 | 13 | 页 | | --- | --- | --- | | （七）合并所有者权益变动表……………………………………第 | 14 | 页 | （八）母公司所有者权益变动表…………………………………第 15 页 | | | 审 计 报 告 天健审〔2024〕3903 号 迈得医疗工业设备股份有限公司全体股东： 一、审计意见 我们审计了迈得医疗工业设备股份有限公司（ ...

Financial Performance - In 2023, the company's operating revenue reached ¥480,220,256, representing a 25.22% increase compared to ¥383,489,867 in 2022[22]. - The net profit attributable to shareholders was ¥99,828,174, up 48.94% from ¥67,024,645 in the previous year[22]. - The net profit after deducting non-recurring gains and losses increased by 51.35% to ¥87,181,211 from ¥57,601,750 in 2022[22]. - The cash flow from operating activities was ¥110,908,655, a 13.94% increase from ¥97,339,070 in 2022[22]. - The company's total assets grew by 10.75% to ¥1,149,858,762 from ¥1,038,264,311 at the end of 2022[22]. - The basic earnings per share rose to ¥0.85, reflecting a 49.12% increase from ¥0.57 in 2022[23]. - The gross profit margin improved from 50.46% in 2022 to 52.27% in 2023, reflecting the company's ability to maintain pricing power despite rising costs[134]. - The company's main business revenue from specialized equipment manufacturing was CNY 476.26 million, a 25.36% increase year-on-year[145]. Research and Development - The company submitted 56 new patent applications during the reporting period, including 6 invention patents[37]. - A total of 32 new patents were granted, with 3 being invention patents, enhancing the company's intellectual property portfolio[37]. - The company has established a comprehensive R&D system integrating eight major modules, including materials, mechanics, and software, reflecting its commitment to high-tech industry standards[95]. - The company has developed multiple core technologies in the field of medical consumables intelligent equipment, establishing itself as a leading domestic manufacturer[92]. - The company has achieved significant advancements in dialysis membrane packaging technology, reducing defects such as blockage (0.1%) and membrane scattering (0.1%) through automated production processes[93]. - The company has received recognition as a national-level specialized and innovative "little giant" enterprise, highlighting its leadership in the medical consumables sector[95]. - The company is focusing on market expansion opportunities in the domestic and international insulin pen markets[96]. Market Position and Strategy - The company has established subsidiaries in Shanghai, Tianjin, and Germany, expanding its market presence[37]. - The company has maintained the highest market share in the medical device industry in China for the years 2021, 2022, and 2023, indicating strong competitive positioning[63]. - The company is actively involved in drafting industry standards, enhancing its influence in the medical device sector, and contributing to the establishment of quality management norms[63]. - The company is committed to expanding its market presence in Europe and developing countries, aiming to increase market penetration and share[182]. - The company plans to expand its market presence and is focusing on new product development, particularly in the medical equipment sector[197]. Corporate Governance - The company has established a comprehensive corporate governance system, including rules for shareholder meetings, board meetings, and supervisory meetings[188]. - The board of directors includes specialized committees to enhance decision-making processes and ensure objective governance[189]. - The company emphasizes transparency in information disclosure, adhering to legal requirements to protect minority investors' interests[190]. - The company has not faced any significant issues regarding independence from its controlling shareholders or related party transactions[190]. - The company held 3 shareholder meetings in 2023, including 1 annual and 2 extraordinary meetings, with a total of 12 proposals approved[188]. Risks and Challenges - The company has detailed potential risks and countermeasures in the report, emphasizing the importance of investor caution[4]. - The company faces risks related to rapid technological updates and the need for continuous innovation to maintain competitive advantages in the medical equipment sector[129]. - The company has a risk of potential contract non-fulfillment, as seen in a past contract with ARSMED, which could adversely affect future financial performance[135]. Innovation and Technology - The company has made significant advancements in technology, achieving recognition for being the first in the domestic market for several products[41]. - The company has developed a high-precision visual real-time inspection platform, which utilizes the self-developed YOLO V4 target detection algorithm to enhance product quality and reduce defect rates[94]. - The company has implemented a GMP data management platform that ensures data integrity and compliance with national regulations, enhancing production process efficiency[94]. - The company is focusing on automation in production processes, gradually replacing manual labor to enhance efficiency and product quality[90]. Talent Development - The company emphasizes talent development and optimization of training strategies to enhance employee loyalty and skills, ensuring sustainable growth[39]. - The company has a total of 113 R&D personnel, accounting for 15.94% of the total workforce, with an average salary of 15.97 million RMB[109]. - The company has a strong focus on talent development, regularly inviting industry experts for lectures and sending employees for further training[111]. Financial Management - The company's accounts receivable at the end of the reporting period amounted to CNY 135.83 million, accounting for 18.86% of current assets and 11.81% of total assets[137]. - Inventory at the end of the reporting period was valued at CNY 143.71 million, representing 19.95% of current assets and 12.50% of total assets[138]. - The company reported a foreign exchange gain of CNY 0.53 million in 2023, down from CNY 0.68 million in 2022[141]. - The company reported a significant increase in minority interests, rising by 345.29% due to profits from subsidiaries and capital increases[166]. Product Development - The company launched new products such as glass pre-filled syringe cleaning and siliconization packaging machines, contributing to revenue growth[25]. - The company has developed a range of automated assembly machines for various medical devices, including blood collection needles, insulin syringes, and infusion devices, showcasing a comprehensive product line[62]. - The company has introduced new products such as automatic assembly machines for POCT diagnostic reagent storage and ENFit nutrition delivery systems, expanding its product offerings[127].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 74,220,852.42, representing a year-on-year increase of 2.08%[5] - The net profit attributable to shareholders decreased by 21.61% to CNY 10,513,161.20[5] - Net profit for Q1 2024 was CNY 9,614,159.23, a decrease of 38.5% from CNY 15,623,627.82 in Q1 2023[23] - The company reported a total profit of CNY 10,488,149.85 for Q1 2024, down from CNY 18,750,630.03 in Q1 2023, a decline of 44.5%[23] - Other comprehensive income after tax for Q1 2024 was CNY 174,622.57, compared to a loss of CNY 63,413.86 in Q1 2023[23] Cash Flow - The net cash flow from operating activities fell significantly by 75.73% to CNY 10,344,617.70[6] - Cash received from sales of goods and services was CNY 103,629,381.64 in Q1 2024, a decrease of 17.7% from CNY 125,874,771.07 in Q1 2023[26] - Total cash inflow from operating activities amounted to $134,126,952.06, while cash outflow was $123,782,334.36, resulting in a net increase of $10,344,617.70[27] - The net cash flow from investment activities was -$23,828,213.47, compared to -$54,165,252.47 in the previous year, indicating an improvement[27] - The ending balance of cash and cash equivalents was $254,292,535.79, up from $209,923,467.15 in the previous year[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,110,516,301.81, a decrease of 3.42% from the end of the previous year[6] - The total current assets were reported at RMB 681,773,053.34, down from RMB 720,324,715.93, indicating a decrease of about 5.3%[17] - The total liabilities decreased to CNY 160,002,589.04 in Q1 2024 from CNY 209,601,710.61 in Q1 2023, a reduction of 23.7%[19] - The total equity increased to CNY 950,513,712.77 in Q1 2024 from CNY 940,257,051.02 in Q1 2023, showing a growth of 1.3%[19] Research and Development - Research and development expenses totaled CNY 9,880,803.80, an increase of 31.44% compared to the previous year[6] - R&D expenses accounted for 13.31% of operating revenue, up by 2.97 percentage points[6] - Research and development expenses increased to CNY 9,880,803.80 in Q1 2024, compared to CNY 7,517,084.03 in Q1 2023, reflecting a growth of 31.5%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,480[12] - The largest shareholder, Lin Junhua, holds 47.42% of the shares, totaling 55,980,400 shares[12] - The company did not report any significant changes in shareholder structure or related party transactions during the quarter[14] Other Financial Metrics - The weighted average return on net assets was 1.17%, down by 0.45 percentage points[6] - Basic earnings per share for Q1 2024 were CNY 0.09, down from CNY 0.11 in Q1 2023[24] - The company reported a significant drop in receivables financing, which decreased to RMB 32,962,046.45 from RMB 63,482,213.11, a decline of approximately 48%[17] - The company’s goodwill remained stable at RMB 10,423,445.72, unchanged from the previous reporting period[17]

广发证券股份有限公司 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为迈得 医疗工业设备股份有限公司（以下简称"迈得医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 科创板股票上市规则》等法律法规的规定，对迈得医疗在 2023 年度募集资金存 放与使用情况进行了核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会《关于同意迈得医疗工业设备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2019 号），中国证券监督管理委 员会同意公司首次公开发行股票的注册申请。公司于 2019 年 11 月首次公开发行 人民币普通股（A 股）股票 2,090 万股，每股面值人民币 1.00 元，每股发行价格 24.79 元，募集资金总额为人民币 51,811.10 万元，扣除发行费用人民币 6,075.96 万元（不含税）后，募集资金净额为 ...

| 序号 | | 召开日期 | | 会议届次 | 审议议案 | | --- | --- | --- | --- | --- | --- | | 1 | 2023 | 年 | 月 1 | 第四届董事会审计委 | 1、审议《关于首次公开发行股票募投项目结项 并将节余募集资金永久补充流动资金的议案》 | | | 15 日 | | | 员会第六次会议 | 2. 审议《关于确认 2022 年度日常关联交易及预 | | | | | | | 计 2023 年度日常关联交易的议案》 | | 2 | 2023 | 年 | 月 2 | 第四届董事会审计委 | 年年度财务报表（未经 1、审议《关于公司 2022 | | | 15 日 | | | 员会第七次会议 | 审计）的议案》 | | | | | | | 年度财务报告的议案》 1、审议《关于公司 2022 案》 年度内部控制评价报告 3、审议《关于公司 2022 | | | | | | | 2、审议《关于公司 2022 年度财务决算报告的议 | | | | | | | 的议案》 | | | 2023 | 年 | 4 月 | 第四届董事会审计委 | | | 3 | 日 25 | ...

按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是迈得 医疗公司董事会的责任。 二、注册会计师的责任 目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2024〕3904 号 迈得医疗工业设备股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了迈得医疗工业设备股份有限公司（以下简称迈得医疗公司）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 第 1 页 共 2 页 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 天健会计师事务所（特殊普通合伙） 中国注册会计师： 中国·杭州 中国注册会计师： 二〇二四年四月二十五日 第 2 页 共 2 页 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致 ...

迈得医疗工业设备股份有限公司 关于续聘会计师事务所的公告 证券代码：688310 证券简称：迈得医疗 公告编号：2024-022 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | --- | --- | --- | --- | | 成立日期 | 2011年7月18日 | 组织形式 | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路128号 | | | | 首席合伙人 | 王国海 | 上年末合伙人数量 | 238 人 | | 上年末执业人员数 | 注册会计师 | | 2,272 人 | | 量 | 签署过证券服务业务审计报告 的注册会计师 | | 836人 | | 2023年业务收入 | 业务收入总额 | | 34.83 亿元 | | | 审计业务收入 | | 30.99 亿元 | | | 证券业 ...

迈得医疗工业设备股份有限公司 2023 年度独立董事述职报告 （一）个人工作履历、专业背景以及兼职情况 张颖辉：1985年1月出生，中国国籍，无境外永久居留权，大学本科学历， 高级会计师、注册会计师、注册税务师。曾任职于天健会计师事务所（特殊普通 合伙）高级项目经理、浙江泰隆商业银行股份有限公司投资经理、滨海润华环保 工程有限公司董事长。主要从事财务管理、内部审计等工作，具备多年财务管理 工作经验。现任浙江吉华集团股份有限公司财务总监，江苏康倍得药业股份有限 公司董事、杭州临江环保热电有限公司监事、浙江恒业电子股份有限公司董事。 2022年5月起任公司独立董事。 （二）独立性说明 作为公司的独立董事，本人不在公司担任除独立董事及董事会各相关专门委 员会成员外的其他职务，并与公司及其主要股东、实际控制人不存在直接或者间 接利害关系，或者其他可能影响其进行独立客观判断关系；独立履行职责，不受 公司及其主要股东、实际控制人等单位或者个人的影响。报告期内，本人符合《上 市公司独立董事管理办法》中规定的独立性要求，不存在影响独立董事独立性的 情况。 二、独立董事年度履职概况 迈得医疗工业设备股份有限公司 2023 年度 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2024-021 迈得医疗工业设备股份有限公司 ● 现金管理产品类型：安全性高、流动性好、具有合法经营资格的金融机构 销售的投资产品； 关于使用部分闲置自有资金进行现金管理的公告 ● 现金管理期限：自公司董事会审议通过之日起 12 个月内； 重要内容提示： ● 现金管理金额：不超过人民币 30,000.00 万元（含本数），在上述额度范 围内，资金可以滚动使用； 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ● 履行的审议程序：2024 年 4 月 25 日公司召开第四届董事会第十九次会议 和第四届监事会十七次会议分别审议通过了《关于使用部分闲置自有资金进行现 金管理的议案》。 一、公司拟使用部分闲置自有资金进行现金管理的情况 （一）现金管理目的 在保证公司正常经营所需流动资金的情况下，提高资金利用效率，合理利用 闲置资金，增加公司收益。 （二）资金来源 公司用于现金管理的资金均为公司暂时闲置的部分自有资金。 （三）投资额度及期限 公司委托理财产品单日最高余额不超过 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2024-024 迈得医疗工业设备股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 24 日 13 点 30 分 召开地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设备股份有限公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 24 日 至 2024 年 5 月 24 日 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | A 股股东 | | 非累积投票议案 | | | | 1 | 关于公司 年度董事会工作报告的议案 2023 | √ | | 2 | 关于公司 2023 年度监事会工作报告的议案 | √ | ...